Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Development
Novo Nordisk and EraCal partner on small-molecule obesity treatment
by Sarah Braner
January 28, 2024
| A version of this story appeared in
Volume 102, Issue 3
Novo Nordisk has reached a deal with EraCal Therapeutics, a spin-off from Harvard University and the University of Zurich, to develop and market an EraCal small molecule to treat obesity. The molecule, through an unspecified mechanism, is intended to control appetite and body weight. Novo will have the exclusive rights to market and develop any resulting drugs, while EraCal is eligible to receive milestone payments of up to about $255 million, along with royalties.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter